Neurobiology of stress and cocaine addiction. Studies on corticotropin-releasing factor in rats, monkeys, and humans.
Stress may contribute to the increased vulnerability to and the development of cocaine addiction. Corticotropin-releasing factor (CRF) activates the hypothalamic-pituitary-adrenal (HPA) axis as well as behavioral and immune processes in response to different environmental and pharmacologic stressors. We hypothesized that CRF might mediate some of the effects of cocaine and as such it may be a link between stressful events and increased vulnerability to cocaine addiction. We demonstrated that blockade of endogenous CRF by a CRF antiserum or a receptor antagonist prevented the cocaine-induced corticosterone response in rats. In male rhesus monkeys and in humans, cocaine selectively increased the amplitude-related, CRF-dependent, elements of pulsatile ACTH release. Cocaine-induced locomotor hyperactivity was antagonized by intracerebroventricular (i.c.v.) administration of a CRF antiserum and a CRF receptor antagonist in rats. In rhesus monkeys, strong correlations were found between behavioral hyperactivity and CRF-dependent elements of pulsatile activity of the HPA axis. Acute cocaine administration induced dose- and time-dependent alterations in hypothalamic and extrahypothalamic/limbic CRF concentrations in rats. Cocaine withdrawal elicited anxiety-like behavior and alterations of CRF concentration in the hypothalamus, amygdala, and basal forebrain. CRF antiserum (i.c.v.) antagonized anxiety-like behavior related to cocaine withdrawal. These data strongly suggest that the HPA axis, brain CRF in particular, may mediate some of the neuroendocrine and behavioral effects of cocaine. The potential involvement of CRF and HPA axis in cocaine-induced psychopathology is hypothesized.
Sarnyai
Z
Z
Laboratory of Neuroendocrinology, Rockefeller University, New York, New York, USA. sarnysz@rockvax.rockefeller.edu
D000324:Adrenocorticotropic Hormone / Q000378:metabolism; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001921:Brain / Q000187:drug effects; D003042:Cocaine / Q000494:pharmacology*; D019970:Cocaine-Related Disorders / Q000503:physiopathology; D003346:Corticotropin-Releasing Hormone / Q000037:antagonists & inhibitors / Q000502:physiology; D000882:Haplorhini; D006801:Humans; D007031:Hypothalamus / Q000502:physiology; D010913:Pituitary-Adrenal System / Q000502:physiology; D051381:Rats; D013312:Stress, Physiological / Q000503:physiopathology*; D013375:Substance Withdrawal Syndrome / Q000503:physiopathology; D019966:Substance-Related Disorders / Q000503:physiopathology*
D000324:Adrenocorticotropic Hormone; D003346:Corticotropin-Releasing Hormone; D003042:Cocaine